Home » Corporate Overview »
Directors
 |
Viropro’s Board of Directors is constituted of dynamic individuals and dedicated experts who are the architects of the company's future. Together, they form a top-ranking team of professionals with proven expertise in the pharmaceutical industry, international business development and corporate finance. Mr Serge Beausoleil, President and Chief Executive Officer Mr. Serge Beausoleil worked for over 12 years in the field of Canadian Securities. He has held various positions at Lévesque Beaubien Geoffrion (Financière Banque Nationale), Burns Fry Ltd (Nesbitt Burns), Valeurs Mobilières Dubeau and finally with CIBC Financial Planning Inc as an Investment Specialist. Mr. Beausoleil is a successful Entrepreneur having done well in personal businesses who likes to face new challenges. His previous experience brings strong expertise in the fields of Finances, Business Management, Sales management, establishment of marketing strategies, partnership agreements and strategic alliance negotiations as well as in communications.
Mr. Beausoleil holds a B.B.A. and an M.Sc. in Economics. He has previously held titles of Chartered Administrator (Adm. A.), Quebec Institute of Financial Planning (Fin. Pl.), as well as the title of Fellow of the Canadian Securities Institute (F.C.S.I.)
Mr Claude Gingras, Vice-President Corporate Affairs For more than 20 years, Mr Gingras worked in the securities industry where he has occupied higher management positions. Over the last 10 years, Mr Gingras has acted as consultant in financial engineering, corporate restructuring and legal documentation. He has also developed and materialized sophisticated investment products such as Small Business Investment Trusts.
Since 2003, Mr Gingras has been involved with several Canadian listed companies where he has successfully structured several millions of dollars in financing.
Mr Gingras has graduated in Economics from Laval University and has also held the title of Fellow of the Canadian Securities Institute (F.C.S.I.)
Dr Rajiv Datar
Dr Datar holds a Ph. D in Bioprocess Technology from the Royal Institute of Technology of Stockholm, Sweden and Post-Doctorate in Biochemical Engineering from the Massasuchetts Institute of Technology (MIT). He has graduated as Biochemist / Chemist from the University of Pune, India and has Post-Graduate studies in Chemical Engineering from the University of Manchester, United Kingdom.
With 22 years experience in Biotechnology and Bio-Business in Senior Technical positions at major pharmaceutical concerns as well as Senior Management positions for publicly-traded or startup biotech, Dr Datar brings an impressive and extensive expertise to the Company.
Moreover, Dr Datar has hands-on knowledge and experience of successful conclusion of business deals, collaborations (across institutions, companies and countries), public issues, in-licensing and out-licensing deals, raising capital, positioning and sale of technologies/departments, takeovers and biotech start-ups. Dr Datar is also member of several Advisory / Boards
Me Emilio Binavince Mr. Binavince, counsel to the law offices of France Viele, was formerly a partner in Gowling, Strathy & Henderson. He was educated in the Philippines (LL.B.), United States (M.C.L., Tulane, LL.M., Harvard) and Germany (Doctoral Studies, Bonn). He is a member of the Bars of Ontario, Saskatchewan and the Philippines. He was the founding chairman, Joint MBA/LL.B. Program and co-Director of the Graduate Faculty of Law at the University of Ottawa. He is an advocate of over thirty years and has appeared as counsel in all levels of Court including the Supreme Court of Canada and various administrative tribunals. Mr. Binavince is active as advisor, corporate director, and legal counsel on business and tax matters of foreign investors and ethnic communities in Canada and of Canadian investors in foreign countries, particularly in the Far East. He is author of numerous articles and books in his area of practice and interest, and specializes in business and tax planning, and, government litigation.
|